Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The dexamethasone suppression test in panic disorder.

F K Judd, T R Norman, G D Burrows

    Pharmacopsychiatry
    |May 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Positive well-being during the menopausal transition: a systematic review.

    Climacteric : the journal of the International Menopause Society·2014
    Same author

    Relaxation theory and practice.

    The Australian journal of physiotherapy·2014
    Same author

    Relaxation, the physiotherapist and the psychiatric patient.

    The Australian journal of physiotherapy·2014
    Same author

    A multidimensional approach to the assessment of pain.

    The Australian journal of physiotherapy·2014
    Same author

    Elevated plasma paroxetine concentrations in a patient treated with a combination of paroxetine and pindolol.

    International journal of psychiatry in clinical practice·2014
    Same author

    Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.

    International clinical psychopharmacology·2004
    Same journal

    A Tribute to Prof. Jules Angst highlighting his Contributions to Clozapine.

    Pharmacopsychiatry·2026
    Same journal

    Correction: Escitalopram and Clonazepam Affect Gasotransmitter-related Enzyme (nNOS, HO-2, CBS) Gene Expression in the Rat Brain.

    Pharmacopsychiatry·2026
    Same journal

    Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

    Pharmacopsychiatry·2026
    Same journal

    Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

    Pharmacopsychiatry·2026
    Same journal

    Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

    Pharmacopsychiatry·2026
    Same journal

    A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.

    Pharmacopsychiatry·2026
    See all related articles

    The dexamethasone suppression test (DST) did not reveal significant differences in cortisol suppression between panic disorder patients and healthy controls. However, panic patients showed higher pre- and post-dexamethasone cortisol levels, suggesting potential cortisol hypersecretion.

    Area of Science:

    • Neuroscience
    • Endocrinology
    • Psychiatry

    Background:

    • Panic disorder is a significant psychiatric condition.
    • The hypothalamic-pituitary-adrenal (HPA) axis is implicated in stress and anxiety disorders.
    • Cortisol dysregulation may play a role in panic disorder pathophysiology.

    Purpose of the Study:

    • To investigate HPA axis function in panic disorder using the dexamethasone suppression test (DST).
    • To compare cortisol suppression patterns between patients with panic disorder and normal controls.

    Main Methods:

    • The dexamethasone suppression test (DST) was administered to 35 patients with panic disorder and 21 healthy controls.
    • Plasma cortisol levels were measured before and after dexamethasone administration.
    • Non-suppression was defined as a post-dexamethasone cortisol level of 4 micrograms/dl.

    Related Experiment Videos

    Main Results:

    • No statistically significant difference was found in the proportion of cortisol non-suppressors between panic disorder patients (29%) and control subjects (9.5%).
    • Both pre- and post-dexamethasone plasma cortisol concentrations were significantly higher in panic disorder patients compared to controls.
    • These findings suggest a potential hypercortisolemia in a subset of panic disorder patients.

    Conclusions:

    • The standard dexamethasone suppression test (DST) may not be a reliable diagnostic marker for panic disorder.
    • Panic disorder patients may exhibit altered cortisol secretion patterns, indicating HPA axis dysregulation.
    • Further research is needed to elucidate the role of cortisol hypersecretion in panic disorder.